RxDoctor Payments Data

Chelsea Buchanan

Nurse Practitioner · Altoona, PANPI 1891151882

Payments from drug & device makers

$613in general payments, 2019–2025

Across 29 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$296
  • Sanofi$102
  • Takeda Pharmaceuticals U.S.A., Inc.$52
  • Phathom Pharmaceuticals, Inc.$35
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25
  • Johnson & Johnson$23
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$59196%
  • Education$224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$613 in reported general payments places this provider in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,223
Medicare patients
317
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab27$731,683
Humira(Cf) PenAdalimumab71$711,089
LinzessLinaclotide130$148,887
CreonLipase/Protease/Amylase38$146,977
XifaxanRifaximin26$87,820
Mesalamine77$40,666
RelistorMethylnaltrexone Bromide14$36,434
TrulancePlecanatide31$33,019
Mesalamine ErMesalamine32$13,164
Dexlansoprazole DrDexlansoprazole24$11,786
Lubiprostone45$11,494
MovantikNaloxegol Oxalate16$9,544
Pantoprazole Sodium523$7,737
Balsalazide Disodium33$6,071
Famotidine326$5,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$23$731,68327 claims
AbbVieLinzess, Creon$296$295,864168 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance$25$157,27371 claims
Takeda Pharmaceuticals U.S.A., Inc.Amitiza$52$3,69113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →